Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.

Chinese biotech Innovent Biologics is reportedly considering a $200 million IPO later this year that could take place in the U.S.

The German company is seeking $22 million to support a clutch of clinical trials designed to expand use of Ameluz in types of skin cancer.

Canadian biotech Adapsyn Bioscience has developed a system that could sift out promising drug candidates from microbes more quickly—catching the eye of a big…

David Hung's decision to join Axovant after selling Medivation to Pfizer for $14 billion now looks more like a gamble that isn't paying off.

The financing will position Evolus to challenge Allergan’s grip on the wrinkle-busting sector by bringing a biosimilar copy of Botox to market.

Last year, a quiet J.P. Morgan Healthcare Conference meant few deals, few major updates. That set the tone for much of the year on the M&A front.

Big Pharma Pfizer will cut around 300 jobs and a number of earlier stage projects from its neuroscience pipeline.